Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Zmień bibliotekę
Tytuł pozycji:

LCK, survivin and PI-3K in the molecular biomarker profiling of oral lichen planus and oral squamous cell carcinoma.

Tytuł :
LCK, survivin and PI-3K in the molecular biomarker profiling of oral lichen planus and oral squamous cell carcinoma.
Autorzy :
Oluwadara O; 1UCLA School of Dentistry, Division of Oral Biology and Medicine, 10833 Le Conte Avenue CHS - Box 951668, Los Angeles, CA 90095-1668, USA.
Giacomelli L
Christensen R
Kossan G
Avezova R
Chiappelli F
Pokaż więcej
Źródło :
Bioinformation [Bioinformation] 2009 Dec 31; Vol. 4 (6), pp. 249-57. Date of Electronic Publication: 2009 Dec 31.
Typ publikacji :
Journal Article
Język :
Imprint Name(s) :
Original Publication: [Singapore] : Biomedical Informatics Pub. Group, 2005-
References :
Braz J Otorhinolaryngol. 2008 Nov-Dec;74(6):861-866. (PMID: 19582342)
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Mar;103 Suppl:S25.e1-12. (PMID: 17261375)
J Am Acad Dermatol. 2002 Feb;46(2):207-14. (PMID: 11807431)
Neoplasia. 2007 Feb;9(2):90-100. (PMID: 17357254)
Oral Dis. 2004 May;10(3):173-8. (PMID: 15089928)
Cytokine Growth Factor Rev. 2002 Apr;13(2):169-83. (PMID: 11900992)
Oral Oncol. 2009 Apr-May;45(4-5):324-34. (PMID: 18805044)
Bioinformation. 2009 Apr 21;3(8):332-9. (PMID: 19707295)
Oral Oncol. 2009 Oct;45(10):e175-9. (PMID: 19628421)
Nat Rev Immunol. 2003 Apr;3(4):317-30. (PMID: 12669022)
J Oral Maxillofac Surg. 2009 Sep;67(9):1914-20. (PMID: 19686929)
Mol Cell Biol. 1993 Dec;13(12):7708-17. (PMID: 8246987)
Crit Rev Oral Biol Med. 2002;13(4):350-65. (PMID: 12191961)
N Z Med J. 2009 Mar 13;122(1291):89-98. (PMID: 19322259)
Cell Biochem Biophys. 2009;55(2):55-79. (PMID: 19672563)
Immunol Rev. 2003 Feb;191:107-18. (PMID: 12614355)
Quintessence Int. 2006 Apr;37(4):261-71. (PMID: 16594357)
Cancer Treat Rev. 2009 Nov;35(7):553-62. (PMID: 19559538)
Oncogene. 2006 Jan 12;25(2):186-97. (PMID: 16116473)
Yonsei Med J. 2009 Aug 31;50(4):464-73. (PMID: 19718393)
Immunol Rev. 2009 Mar;228(1):9-22. (PMID: 19290918)
Quintessence Int. 2004 Mar;35(3):223-7. (PMID: 15119681)
Arch Oral Biol. 2006 Dec;51(12):1093-103. (PMID: 16914114)
Biochim Biophys Acta. 2008 Jan;1784(1):159-85. (PMID: 17997386)
Oncogene. 2006 Mar 16;25(12):1693-5. (PMID: 16186791)
Mol Cell Biol. 2008 Jan;28(2):630-41. (PMID: 17998336)
J Biol Chem. 1993 Sep 25;268(27):20031-6. (PMID: 8397196)
J Pharmacol Exp Ther. 2005 Oct;315(1):36-41. (PMID: 16014572)
Adv Cancer Res. 2009;102:19-65. (PMID: 19595306)
Semin Radiat Oncol. 2002 Oct;12(4):341-51. (PMID: 12382192)
Mol Cell Biol. 2006 Nov;26(22):8655-65. (PMID: 16966372)
Oral Dis. 2008 Apr;14(3):229-43. (PMID: 18298420)
Oral Oncol. 2004 Oct;40(9):964. (PMID: 15380177)
Contributed Indexing :
Keywords: biomarker; cancer; cellular immunity; oral carcinoma
Entry Date(s) :
Date Created: 20101027 Date Completed: 20110714 Latest Revision: 20211020
Update Code :
PubMed Central ID :
Czasopismo naukowe
T cell signaling is critical in oral lichen planus (OLP) based on the pathogenesis of this chronic inflammatory autoimmune mucocutaneous lesion. Lck plays a key role in T cell signaling; ultimately this signaling affects other targets such as PI-3K. Excessive activity in PI-3K inhibits apoptosis and promotes uncontrolled cell growth. Molecular biomarker profiling in OLP, Chronic Interface Mucosities (CIM), Epithelial Dysplasia (EpD) and Oral Squamous Cell Carcinoma (SCCA) with application of the principle of biomarker voting may represent a new frontier in the diagnosis, assessment and the arguable debate of OLP transformation to cancer. The presence of Lck, PI-3K and Survivin, a cancer specific anti-apoptotic protein was assessed, using immunohistochemistry and tissue micro-array on patient samples, in OLP, SCCA, CIM and EpD. Lck expression was very high in 78.6 % of OLP patients compared to 3.7% in SCCA; PI-3K was high in 63% of SCCA, 100% of EpD, and 35.7% OLP cases. Survivin was high in 64.3% of OLP cases, 96.3% of SCCA, and 100% of EpD. CIM cases may be slightly different molecularly to OLP. Taken together, our data suggest that biomarker protein voting can be effectively used to isolate high-risk OLP cases. Specifically, we show data with four remarkable cases demonstrating that molecular factors are predictive of histopathology. We conclude that it is safer to treat OLP as premalignant lesions, to adopt aggressive treatment measure in histopathologic described well and moderately differentiated SCCA, and to monitor progress of these diseases molecularly using individualized auto-proteomic approach. The use of Lck inhibitors in OLP management needs to be investigated in the future.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies